Confers lenvatinib resistance in HCC cells by promoting AREG expression, thereby activating the EGFR-ERK1/2-CyclinD1 signaling pathway (Hu et al., 2025). This evidence concerns the gene MAPK3 and hepatocellular carcinoma.